Fort Washington Investment Advisors Inc. OH Sells 66,156 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Fort Washington Investment Advisors Inc. OH reduced its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 17.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 309,891 shares of the biopharmaceutical company's stock after selling 66,156 shares during the period. Fort Washington Investment Advisors Inc. OH's holdings in Gilead Sciences were worth $34,723,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of GILD. Newbridge Financial Services Group Inc. purchased a new position in shares of Gilead Sciences during the 4th quarter worth $33,000. Annis Gardner Whiting Capital Advisors LLC increased its stake in Gilead Sciences by 158.8% in the fourth quarter. Annis Gardner Whiting Capital Advisors LLC now owns 352 shares of the biopharmaceutical company's stock valued at $33,000 after purchasing an additional 216 shares during the last quarter. Morton Brown Family Wealth LLC acquired a new stake in Gilead Sciences in the 4th quarter worth about $35,000. Whipplewood Advisors LLC purchased a new stake in Gilead Sciences in the 4th quarter valued at about $35,000. Finally, Synergy Investment Management LLC acquired a new position in shares of Gilead Sciences during the 4th quarter valued at about $40,000. Institutional investors and hedge funds own 83.67% of the company's stock.

Gilead Sciences Stock Up 2.5%

GILD traded up $2.75 on Thursday, reaching $112.05. 7,023,598 shares of the company traded hands, compared to its average volume of 7,745,911. Gilead Sciences, Inc. has a 52-week low of $62.69 and a 52-week high of $119.96. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20. The company has a market cap of $139.38 billion, a price-to-earnings ratio of 302.84, a PEG ratio of 0.71 and a beta of 0.29. The stock's 50 day moving average price is $105.40 and its 200-day moving average price is $101.91.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last posted its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. The company had revenue of $6.67 billion for the quarter, compared to analyst estimates of $6.77 billion. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. The business's revenue was down .3% compared to the same quarter last year. During the same period last year, the company earned ($1.32) earnings per share. On average, sell-side analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 27th. Stockholders of record on Friday, June 13th will be issued a dividend of $0.79 per share. The ex-dividend date is Friday, June 13th. This represents a $3.16 annualized dividend and a dividend yield of 2.82%. Gilead Sciences's payout ratio is 66.53%.

Insider Buying and Selling

In other Gilead Sciences news, CEO Daniel Patrick O'day sold 10,000 shares of the business's stock in a transaction on Friday, May 30th. The shares were sold at an average price of $110.42, for a total value of $1,104,200.00. Following the sale, the chief executive officer now owns 620,268 shares of the company's stock, valued at $68,489,992.56. The trade was a 1.59% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of Gilead Sciences stock in a transaction dated Thursday, May 22nd. The shares were sold at an average price of $107.52, for a total transaction of $3,010,560.00. Following the sale, the insider now owns 121,152 shares in the company, valued at approximately $13,026,263.04. This trade represents a 18.77% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 43,000 shares of company stock valued at $4,630,310 over the last three months. 0.27% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on GILD shares. BMO Capital Markets upped their price target on shares of Gilead Sciences from $110.00 to $115.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 12th. Royal Bank of Canada upped their price objective on Gilead Sciences from $84.00 to $90.00 and gave the stock a "sector perform" rating in a report on Wednesday, February 12th. Wells Fargo & Company lifted their target price on Gilead Sciences from $120.00 to $140.00 and gave the company an "overweight" rating in a report on Wednesday, March 5th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a research note on Wednesday, May 21st. Finally, The Goldman Sachs Group lifted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a research note on Wednesday, February 12th. Nine equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and three have assigned a strong buy rating to the stock. Based on data from MarketBeat, Gilead Sciences has a consensus rating of "Moderate Buy" and an average target price of $110.55.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.